Monitor the EHA 2026 poster presentation on June 13 for data quality and any partnership discussions. The clinical trial application timeline (H2 2026) is the next major catalyst. No immediate trading action warranted.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 12 $4.17entry
- T+1 · 6mo ago −0.24%α −0.82% · $4.16
- T+5 · 6mo ago −1.92%α −2.00% · $4.09
- T+20 · 5mo ago −9.11%α −7.39% · $3.79
- T+60 · 3mo ago −28.18%α −32.56% · $3.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion announced it will present preclinical data for EVX-04, an off-the-shelf therapeutic AML vaccine, at the EHA 2026 Congress in June. The data is preclinical and the company plans to submit a clinical trial application in H2 2026. This is a routine pipeline update with no financial data or near-term catalyst.
Key Facts
- Evaxion to present functional characterization data for EVX-04 at EHA 2026 Congress on June 13, 2026
- EVX-04 is an off-the-shelf therapeutic vaccine targeting acute myeloid leukemia (AML)
- Preclinical data shows EVX-04 prevents tumor growth in preclinical models
- Company plans to submit a clinical trial application in the second half of 2026
- No financial data, revenue, or guidance provided in the filing
Financial Impact
No financial impact disclosed; preclinical milestone with no revenue or cost figures
Risk Factors
- Preclinical data may not translate to clinical success
- Company requires additional capital to fund clinical development
- AML vaccine market is competitive with established therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003279 |
| Document: f6k_051226.htm | 0001171843-26-003279 |
| Document: 0001171843-26-003279-index-headers.html | 0001171843-26-003279 |
| Document: 0001171843-26-003279-index.html | 0001171843-26-003279 |
| Document: 0001171843-26-003279.txt | 0001171843-26-003279 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers